99% Purity Nilotinib Hydrochloride Monohydrate Pharmaceutical Intermediate Nilotinib Raw Material Powder Anticancer Nilotinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Model NO.: Dsung-Nilotinib
• Product Name: Nilotinib
• Name: Nilotinib Powder
• Appearance: White to off-White Powder
• Grade: Pharmaceutical Grade
• Assay: HPLC 99%
• Application: Pharmaceutical Intermediate
• Specific: COA
• Test Method: HPLC
• Shelf Life: 2 Years
• CAS No.: 641571-10-0
• Mf: C28h22f3n7o
• MW: 529.527
• Density: 1.36
• Melting Point: 230-242 C
• Refractive Index: 1.65
• Transport Package: Negotiable
• Specification: 99%
• Trademark: D-Sung
• Origin: Shaanxi
• Production Capacity: 500kg/Month

Product Description

99% Purity Nilotinib Hydrochloride Monohydrate Pharmaceutical Intermediate Nilotinib Raw Material Powder Anticancer Nilotinib

 

Product Description

Product Details

Product Name	Nilotinib
CAS No.	641571-10-0
MF	C28H22F3N7O
MW	529.527
Appearance and shape	White to off-white powder

Nilotinib is an off-white solid chemical.  The molecular formula is C28H22F3N7O and the molecular weight is 529.51600.  Nilotinib is an antitumor drug, and it is mainly used chronic or accelerated adult patients with Philadelphia chromosome-positive chronic myelogenous leukemia who are resistant or intolerant to previous treatments.

Application & Function

Function:
Nilotinib (Tasigna) is a new type of targeted cancer therapy, which belongs to the tyrosine kinase inhibitor, for the treatment of Gleevec (imatinib) resistant chronic myelogenous leukemia (CML) patients, curative effect.
Nilotinib is a molecular structure of imatinib imatinib improved and has better selectivity to BCR-ABL kinase activity, inhibition of tyrosine kinase compared with imatinib 30 times stronger inhibition on imatinib resistant mutant BCR-ABL kinase activity. It also inhibits the activity of KIT and PDGFR kinase.
Application:
A powerful and precise second-generation tyrosine kinase inhibitor, effective in treating patients with drug-resistant or intolerant chronic myelogenous leukemia.
Nilotinib is an antitumor drug, and it is mainly used clinically to treat chronic myelogenous leukemia that is resistant to Gleevec (imatinib).

Specification